肝硬化并发急性肾损伤诊治进展

doi:10.3969/j.issn.1672-5069.2022.06.003

Abstract

Han Fang, Li Jiazheng, Nan Yuemin. Management of acute kidney injury in patients with livercirrhosis[J]. Journal of Practical Hepatology, 2022, 25(6): 768-771.

[1] Ginès P, Solà E, Angeli P, et al. Hepatorenal syndrome. Nat Rev Dis Primers, 2018, 4(1): 23-39.
[2] Huelin P, Solà E, Elia C, et al. Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: a prospective study. Hepatology, 2019, 70(1): 319-333.
[3] Tandon P, James MT, Abraldes JG, et al. Relevance of new definitions to incidence and prognosis of acute kidney injury in hospitalized patients with cirrhosis: a retrospective population-based cohort study. PLoS One, 2016, 11(8): e0160394- e0160405.
[4] 王文娟, 宋琦,丁惠国. 肝硬化患者急性肾损伤的临床特点及危险因素分析. 中华内科杂志, 2018, 57(12): 912-916.
[5] 王洪玲,田洁,韩涛.失代偿性肝硬化伴发急性肾损伤的危险因素分析. 中华肝脏病杂志, 2014,22(6): 420-424
[6] Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. Brit Med J,2020,370: m2687-m2702.
[7] Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol, 2015, 62(4): 968-974.
[8] Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021, 74(2): 1014-1048.
[9] Gifford F J,Morling J R, Fallowfield JA. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. Aliment Pharmacol Ther, 2017,45(5):593-603.
[10] Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology, 2016, 63(3): 983-992.
[11] Song T,Rössle M, He F, et al. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis. Dig Liver Dis,2018, 50(4): 323-330.
[12] European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. JHepatol, 2018, 69(2): 406-460.

[1]	Han Tao, Liu Yandi, Hu Jiaxuan. Advances in the management of patients with liver disease with kidney injury [J]. Journal of Practical Hepatology, 2022, 25(6): 761-763.
[2]	Jiang Yingying, Ding Huiguo. Current status and challenges of clinical management of cirrhotics with acute kidney injury [J]. Journal of Practical Hepatology, 2022, 25(6): 764-767.
[3]	Shen Yiliang, Shen Dongyuan, Chen Yongying, et al.. Qualitative evaluation of intrahepatic nodules in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 836-839.
[4]	Lin Xiuhui, Li Nan, Zhang Jiaozhen, et al.. Polymorphisms of PNPLA3 and PRKAA1 genes and their correlation to liver cirrhosis in patients with hepatitis B viral infection [J]. Journal of Practical Hepatology, 2022, 25(6): 844-847.
[5]	Zhu Haiyan, Fan Xiaotang. Nomogram model in predicting portal venous thrombosis in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 848-852.
[6]	Sun Jing, Zhang Weiwei, Ma Zhiyong, et al.. Prevention of varices re-bleeding in patients with liver cirrhosis undergoing transjugular intrahepatic portosystemie stent and gastric coronary vein embolization [J]. Journal of Practical Hepatology, 2022, 25(6): 853-856.
[7]	Li Xiang, Zhang Tieying, Zhang Xuhui, et al.. Evaluation of esophageal varices by semi-quantitative scoring based on ultrasonography in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 857-860.
[8]	Zhang Yaohui, Zheng Zhangzeng, Gao Xing, et al.. Contrast-enhanced ultrasound time-intensity curve in assessment of liver nodules in cirrhotic patients [J]. Journal of Practical Hepatology, 2022, 25(6): 861-864.
[9]	Zhan Zhiyuan, Shen Yang, Wang Fanbing. Short-term hemostatic effect of endoscopic variceal ligation and omeprazole and octreotide combination in the treatment of cirrhotics with first esophageal varices bleeding [J]. Journal of Practical Hepatology, 2022, 25(6): 865-868.
[10]	Shen Yipeng, Zhu Junfeng. Spontaneous bacterial peritonitis in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 909-912.
[11]	Nan Yuemin, Li Jiazheng. Liver cirrhosis and infections: the state of the disease [J]. Journal of Practical Hepatology, 2022, 25(5): 609-611.
[12]	Luo Nan, Li Rongkuan. Spontaneous bacterial peritonitis in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(5): 616-619.
[13]	Gong Hao, Huang Li, Zhang Qinghong, et al.. Diagnostic efficacy of urine microalbumin, β2-microglobulin and N-acetyl-beta-glucosaminidase levels for renal injury in patients with decompensated liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(5): 681-684.
[14]	Li Ting,Mao Xiaorong, Zhang Xuemei, et al.. Comparison of incidence of portal vein thrombosis in cirrhotics with hypersplenism after undergoing splenectomy or TIPS [J]. Journal of Practical Hepatology, 2022, 25(5): 685-688.
[15]	Chronic Disease Management Branch, China Pharmaceutical Biotechnology Association. Expert consensus on the management of diabetes mellitus in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(5): 0-S1.

Management of acute kidney injury in patients with livercirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments